newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - SEPTERNA INC

  • Explicit Guidance:

    • SCP-479 (Hyperparathyroidism) Phase 1 Readout: Anticipated data release in Q1 2027.
    • SCP-204 (Graves' Disease/Thyroid Eye Disease) Phase 1 Initiation: Expected to commence in Q1 2027.
    • Phase 1 Data Share for SCP-204: Healthy volunteer data expected prior to end of 2027.
    • Phase 2 Initiation (SCP-479): Targeted for the second half of 2026.
    • Novo Partnership Milestone: First development candidate selected and planned for advancement (announced in quarterly earnings; collaboration started mid-2025).
  • Business-Segment Outlook:

    • SCP-479 (PTH1R Agonist):
      • Targeting 150 subjects in a Single/Multiple Ascending Dose (SAD/MAD) study in Australia, including a food effect study.
      • Target PK/PD Biomarkers (Healthy Volunteers): Reduction in endogenous PTH levels by ~50%; increase in serum calcium by ~0.5 mg/dL (starting dose) and ~1.0 mg/dL (high dose) to match the performance of current injectable peptide standard (YorvPath).
      • Half-life Projection: Observed half-life of 3–4 days (target range 40–80 hours), supporting once-daily dosing.
    • SCP-204 (TSHR Antagonist):
      • Targeting Graves' disease and thyroid eye disease (TED) via selective TSHR binding to block autoantibodies.
      • Target PK/PD Biomarkers (Healthy Volunteers): Expected increase in endogenous TSH levels; suppression of thyroid hormones (T4) at higher doses.
      • Half-life Projection: Estimated human half-life of 20–40 hours.
      • Dosing Strategy: Aiming for dose-selective options to either normalize thyroid function or fully suppress it based on disease severity.
    • SCP-631 (MRGPRX2 Negative Allosteric Modulator):
      • Phase 1 completed (March 2027); currently between Phase 1 and Phase 2.
      • Strategic Pivot: Moving away from large Phase 2 chronic spontaneous urticaria (CSU) studies toward smaller, signal-finding studies to validate mechanisms in new indications.
      • New Indication Exploration: Prioritizing migraine (leveraging mast cell activation and PACAP agonism data), alongside interstitial cystitis and asthma.
    • Osteoporosis Program (PTH Receptor Agonist):
      • Developing a distinct short-acting oral compound (differentiation from long-acting SCP-479) to mimic anabolic bone formation effects of short-acting peptides.
  • Market and Competitive Outlook:

    • Hyperparathyroidism Market:
      • Target Population: ~70,000–80,000 patients in the US (post-surgical).
      • Unmet Need: Current standard of care (Calcium/Vit D) is insufficient for severe cases; injectable peptide (YorvPath) faces adherence issues due to daily injections.
      • Competitive Differentiation: SCP-479 is the only oral PTH replacement in development. Differentiation from competitor Encallrate (CaSR agonist) via mechanism: SCP-479 replaces missing PTH directly (suitable for post-surgical patients), whereas Encallrate requires functional parathyroid tissue.
      • Market Expansion: Oral therapy expected to expand treatable population to moderate patients and provide convenience for severe patients currently on injectables.
    • Graves' Disease/TED Market:
      • Unmet Need: High relapse rates with antithyroid drugs; limited novel therapies in decades; few options for mild TED and significant need for moderate-severe cases.
      • Competitive Landscape: SCP-204 targets the root cause (autoantibodies at TSHR receptor) for both Graves' and TED simultaneously, a novel approach compared to current symptomatic treatments.
    • Mast Cell (MRGPRX2) Market:
      • Shifting strategy from broad CSU trials to targeted "signal-finding" studies in migraine to validate efficacy before larger commitments.
  • Macro / Industry Outlook:

    • Regulatory Strategy: Leveraging Phase 1 healthy volunteer data as a robust proof-of-concept for patient efficacy based on identical PTH receptor biology between healthy volunteers and patients.
    • Clinical Development Efficiency: Planning to integrate chronic toxicology studies to enable open-label extension enrollment for Phase 3 patients immediately upon benefit confirmation.
  • Strategic Initiatives:

    • Novo Collaboration: Ongoing partnership covering five targets (four concurrent programs); first candidate selected for forward development in late 2025/early 2026 (post-announcement).
    • Pipeline Expansion: Advancement of a fourth program for osteoporosis, distinct from the hyperparathyroidism program due to specific dosing half-life requirements for bone anabolism.
    • Platform Validation: Successful identification of two distinct binding pockets on GPCRs (PTH1R and TSHR) enabling oral small molecules to mimic peptide function, a breakthrough area historically difficult for competitors.
  • Risks and Headwinds to Outlook:

    • Clinical Outcome Risks: Failure to achieve projected biomarker shifts (50% PTH reduction, 0.5–1.0 mg/dL calcium increase for SCP-479; TSH elevation and T4 suppression for SCP-204) could halt development.
    • Safety Concerns: SCP-204 preclinical toxicology showed exaggerated on-target pharmacology (hypothyroidism), requiring careful dose titration in humans.
    • Timing Delays: Phase 2 initiation for SCP-479 relies on completing chronic toxicology studies before Q2/Q3 2026; delays here could push patient enrollment.
    • Competitive/Regulatory Uncertainty: Potential for Encallrate to demonstrate efficacy in post-surgical patients (currently considered mechanistically unsuitable) or for new competitive oral GPCR drugs to enter the space.
    • Phase 1 Failure Risk: While healthy volunteer data is a strong predictor, clinical failure in patient populations remains a risk.
  • Management Tone on the Future:

    • Confidence: High confidence in the "Native Complex Platform" success, emphasizing that SCP-479 and SCP-204 mimic peptide effects better than previous attempts.
    • Strategic Pivot: Decisive and data-driven shift in the MRGPRX2 program, moving from large-scale CSU trials to focused migraine validation to conserve resources and identify signal.
    • Differentiation: Strong conviction in the unique mechanism of SCP-479 for post-surgical patients compared to mechanism-based competitors (Encallrate).
    • Market Outlook: Belief that oral therapies will significantly expand the treatable patient population in hypoparathyroidism and offer a novel, potentially curative approach for Graves' disease/TED.
  • Miscellaneous:

    • Trial Designs: SCP-479 Phase 2 will utilize a titration protocol similar to YorvPath (dosing drug while reducing calcium/vitamin D supplements).
    • Pharmacology: SCP-631 is characterized by a unique negative allosteric modulation mechanism with a slow off-rate, aiming for ~99% receptor occupancy.
Company
SEPTERNA INC
Keywords
SEPTERNA INC